Antitumor activity of nab-sirolimus versus mTOR inhibitors temsirolimus, sirolimus, and everolimus in A549 NSCLC xenografts. This is an ASCO Meeting Abstract from the 2024 ASCO Annual Meeting I. This ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results